BioNTech CEO Şahin: There May Be Cuts in Vaccine Production

BioNTech CEO Şahin: There May Be Cuts in Vaccine Production BioNTech CEO Şahin said: There may be cuts in vaccine production. Uğur Şahin stated that they are trying to increase production with Pfizer and stated that there may be interruptions in vaccine supply until other vaccines arrive. Şahin said that vaccine tests for the mutation of the coronavirus continue. While vaccination for the coronavirus epidemic continues in Europe, BioNTech CEO Uğur Şahin warned about the vaccine supply. Speaking to the German weekly magazine Der Spiegel, Şahin stated that together with Pfizer, they continue to work on increasing vaccine production at full speed, and there may be interruptions in vaccine supply until other vaccines are applied. Authorized institutions in Europe approved the use of the BioNTech-Pfizer vaccine, and vaccination started on December 27. However, some vaccination centers in Germany were temporarily closed as of December 27. BioNTech CEO Şahin stated that they had to fill the gap created by the lack of approval for other vaccines in the continent with their own vaccines. It requires the relevant authorities in Europe to approve Moderna's vaccine on January 6. Şahin, who also made statements about the variant of the coronavirus first detected in England, stated that the vaccine they developed could be effective against the mutation. Şahin stated that they are continuing their work on this subject and that the tests will be completed soon. Şahin noted that they are working to keep the vaccine, which should be kept at 70 degrees below zero, to be stored more easily, and that the new generation vaccine can be stored at higher degrees towards the end of the summer.